STAT : Pharmalittle: Biogen ALS drug trial yields mixed signals; Novartis makes U.S. growth its top priority
After a torrid couple of years, Biogen can be forgiven for making the most of new data on its tofersen drug for ALS.
STAT : Pharmalittle: Biogen ALS drug trial yields mixed signals; Novartis makes U.S. growth its top priority
After a torrid couple of years, Biogen can be forgiven for making the most of new data on its tofersen drug for ALS.